

### Australia Opportunity Analysis: Comparing Australian Clinical Practice to CONQUEST Quality Standards (2015-2019)

- ❖ An observational, longitudinal, descriptive study for the CONQUEST programme
- ❖ Focused on a population of high-risk patients with diagnosed or potential COPD.
- ❖ Analysis sample was identified in 2019 and in each previous year back to 2015.
- ❖ Routinely collected primary care data was assessed over the relevant time frame for each outcome; the 12 months before or after 1 January of each study year.
- ❖ 2019 was chosen as the key year for the data as it provides the most up-to-date information prior to the COVID-19 pandemic.





Collaboration On Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care.

# Patterns of care in the management of high-risk COPD in Australia (2015-2019): an observational study for the CONQUEST quality improvement program.

Christine Jenkins, Andrew P Dickens, Alexander Evans, Porsche Le Cheng, Florian Heraud, Kerry Hancock, Anita Sharma, Belinda Cochrane, Alexander

Roussos, Chantal Le Lievre, John Blakey, Sinthia Bosnic-Anticevich, Victoria Carter, Angelina Catanzariti, Clare Ghisla, Mark Hew, Brian Ko, Thao Le,

Paul Leong, Vanessa M McDonald, Chi Ming Lau, Jennifer L Perret, Rachel Pullen, Kanchanamala Ranasinghe, Joan B Soriano, Deb Stewart, Marije van

Melle, Russell Wiseman, and David Price

Lancet Regional Health – Western Pacific, 2025;58: 101555

CONQUEST is conducted by Optimum Patient Care Global and the Observational and Pragmatic Research Institute and is co-funded by Optimum Patient Care Global and AstraZeneca




# **Aims & Methods**





#### **Aims of the Australian Opportunity Analysis**

To comprehensively review management opportunities for high-risk COPD patients in Australia, with reference to national and international guidelines, and also the CONQUEST quality standards<sup>1</sup>









for the CONQUEST Opportunity Analysis:

The Optimum
Patient Care
Research
Database
Australia
(OPCRDA)




- Data & analyses have been derived from primary care electronic medical records (EMRs) within the OPCRDA.
- OPCRDA is established and maintained by Optimum
   Patient Care Australia (OPCA).



### **Australia Opportunity Analysis: Data Source & Study Populations**





# **Key Australian Results & Take Away Messages**





### Australian Opportunity Analysis: Key Opportunities Identified within High-risk Patient Cohorts



#### In 2019, of the eligible patients identified

- ➤ 6.2% (1,045/16,816) potential undiagnosed COPD patients
- > 35.2% (87/247) newly diagnosed COPD patients
- > 24.9% (1,476/5,922) already diagnosed COPD patients

were categorised as high-risk\*

Opportunities to reduce this high-risk status across all cohorts within the study periods include:

1

Greater use of spirometry assessment, particularly newly diagnosed patients

Improved guideline and evidence-based inhaled therapy prescribing

3

2

Increased assessment of cardiovascular risk status

Increase provision of regular COPD clinical reviews and non-pharmacological interventions

4

\*High-risk patients had a history of ≥2 exacerbations (or COPD-like exacerbations if undiagnosed) in the <u>previous</u> 24 months


Jenkins et al. Lancet Regional Health – Western Pacific 2025;58: 101555 https://doi.org/10.1016/j.lanwpc.2025.101555








# Substantial opportunity for greater performance and recording of spirometry assessment in patients with newly diagnosed COPD





### **Opportunity for Increased Assessment of Cardiovascular Risk Status**

In 2019, 92.9% of patients without an existing cardiac diagnosis had no cardiac risk assessment recorded in the 12 months either side of 1st Jan 2019



Key trends in assessment and interventions for already diagnosed COPD patients meeting high-risk criteria. Jenkins et al. Lancet Regional Health – Western Pacific 2025;58: 101555








### Scope to improve guideline and evidence-based inhaled therapy prescribing






39.5% of already diagnosed and 48.3% of newly diagnosed high-risk patients had no evidence of prescribed inhaled therapy (2019)



### Scope to improve provision of COPD reviews and non-pharmacological interventions: 2019 Focus



## **Conclusions from Australian Data**





### **Conclusions**

Considerable opportunities to improve the identification and management of patients with COPD exist in the Australian primary care setting


Responding to these opportunities would align clinical care with national and international guidance, in terms of the diagnosis, assessment, treatment and long-term follow-up of patients at high-risk of future COPD exacerbations

❖ If applied in practice CONQUEST quality standards have the potential to improve long-term outcomes for those at greatest cardiopulmonary risk, even if not already diagnosed with COPD











### For More Information on the Findings of the Australian Opportunity Analysis Manuscript

➤ View the full article here: <a href="https://doi.org/10.1016/j.lanwpc.2025.101555">https://doi.org/10.1016/j.lanwpc.2025.101555</a>

